#62
Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians need to actively screen older patients for cannabis use since many seniors use cannabis without disclosing it, creating dangerous risks of drug-drug interactions with their medications and masking the true cause of adverse health effects. This communication gap means doctors cannot provide informed guidance on safe dosing, cannabinoid content, or potential harms specific to aging physiology, leaving vulnerable patients without evidence-based counsel on a substance they’re already consuming.
Recent evidence indicates that older adults increasingly use cannabis without disclosing this use to their physicians, while clinicians often lack confidence in discussing cannabis with elderly patients, creating a significant care gap in this population. This communication breakdown is particularly concerning because older adults frequently take multiple medications with potential drug-drug interactions involving cannabis, and they may have complex medical conditions where cannabis use could complicate treatment plans or mask underlying symptoms. The lack of transparency means clinicians cannot provide appropriate monitoring for adverse effects, drug interactions, or contraindications that may be especially relevant in geriatric populations with compromised organ function and polypharmacy. Additionally, seniors may be self-treating legitimate medical conditions without evidence-based guidance, potentially delaying diagnosis or treatment of serious underlying diseases. Clinicians should proactively create a non-judgmental environment for discussing cannabis use with older patients, ask about use during medication reconciliation, and educate themselves on cannabis pharmacology and interactions relevant to this vulnerable population. To improve patient outcomes, physicians need training in cannabis counseling and seniors need clear guidance about risks, benefits, and interactions specific to their age group and medication regimens.
“The real clinical problem here isn’t that seniors are using cannabis, it’s that they’re not telling us, which means we can’t manage drug interactions, monitor dosing, or adjust their other medications appropriately. Until we create office environments where patients feel safe disclosing cannabis use without judgment, we’re flying blind on a significant portion of our elderly population’s medication regimen.”
? The apparent migration of older adults toward cannabis dispensaries rather than primary care providers for symptom management represents a concerning care coordination gap with potentially serious implications for drug interactions, contraindications, and disease monitoring. This phenomenon likely reflects multiple drivers including physician discomfort with cannabis discussions, patients’ perception that doctors won’t be receptive, lingering stigma, and the accessibility of dispensary staff who may actively counsel on symptom relief. However, important caveats deserve emphasis: dispensary recommendations typically lack the individualized medical context that clinicians possess, cannabis effects in older adults (who often take multiple medications and have polypharmacy concerns) remain incompletely characterized, and patients using cannabis surreptitiously cannot benefit from appropriate safety surveillance or integrated treatment planning. Healthcare providers should recognize this gap as a call to proactively normalize non-judgmental cannabis use discussions during routine visits, explicitly ask about cannabis consumption as part of standard medication reconciliation,
💬 Join the Conversation
Have a question about how this applies to your situation?
Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers?
Join the forum discussion →
Have thoughts on this? Share it:
